OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Amar Ali, Steve Baín, Debbie Hicks, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1595-1622
Open Access | Times Cited: 45
Amar Ali, Steve Baín, Debbie Hicks, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1595-1622
Open Access | Times Cited: 45
Showing 26-50 of 45 citing articles:
The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study
Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, et al.
Cardiology and Therapy (2020) Vol. 10, Iss. 1, pp. 189-199
Open Access | Times Cited: 9
Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, et al.
Cardiology and Therapy (2020) Vol. 10, Iss. 1, pp. 189-199
Open Access | Times Cited: 9
Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society
Raffaele Napoli, Gloria Formoso, Salvatore Piro, et al.
Nutrition Metabolism and Cardiovascular Diseases (2020) Vol. 30, Iss. 11, pp. 1926-1936
Closed Access | Times Cited: 8
Raffaele Napoli, Gloria Formoso, Salvatore Piro, et al.
Nutrition Metabolism and Cardiovascular Diseases (2020) Vol. 30, Iss. 11, pp. 1926-1936
Closed Access | Times Cited: 8
Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?
Jennifer Snaith, Jerry R. Greenfield
The Medical Journal of Australia (2022) Vol. 217, Iss. 3, pp. 126-128
Open Access | Times Cited: 5
Jennifer Snaith, Jerry R. Greenfield
The Medical Journal of Australia (2022) Vol. 217, Iss. 3, pp. 126-128
Open Access | Times Cited: 5
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Dalal Y. Al-Bazz, John Wilding
Future Cardiology (2020) Vol. 16, Iss. 2, pp. 77-88
Closed Access | Times Cited: 6
Dalal Y. Al-Bazz, John Wilding
Future Cardiology (2020) Vol. 16, Iss. 2, pp. 77-88
Closed Access | Times Cited: 6
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Ammar Chaudhary, Fadi Alreefi, Mohammad Aziz
CJC Open (2021) Vol. 3, Iss. 5, pp. 646-657
Open Access | Times Cited: 4
Ammar Chaudhary, Fadi Alreefi, Mohammad Aziz
CJC Open (2021) Vol. 3, Iss. 5, pp. 646-657
Open Access | Times Cited: 4
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Evangelia Makri, Eleftheria Makri, A. Goulas, et al.
Annals of Gastroenterology (2024)
Open Access
Evangelia Makri, Eleftheria Makri, A. Goulas, et al.
Annals of Gastroenterology (2024)
Open Access
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Mukesh Nandave
(2024), pp. 33-149
Closed Access
Mukesh Nandave
(2024), pp. 33-149
Closed Access
Effects of antidiabetic medications on cardiovascular outcomes
Marco Shiu Tsun Leung, Shangzhe George Lin, Leshanth Uthayanan, et al.
Journal of Cardiac Surgery (2020) Vol. 35, Iss. 10, pp. 2759-2767
Open Access | Times Cited: 3
Marco Shiu Tsun Leung, Shangzhe George Lin, Leshanth Uthayanan, et al.
Journal of Cardiac Surgery (2020) Vol. 35, Iss. 10, pp. 2759-2767
Open Access | Times Cited: 3
Crosstalk Between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger- 1 and 3 in Cardiometabolic Diseases
Al-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, et al.
Authorea (Authorea) (2024)
Open Access
Al-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, et al.
Authorea (Authorea) (2024)
Open Access
Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet
Evangelia Makri, Konstantinos Xanthopoulos, Spyros Pettas, et al.
HORMONES (2024)
Closed Access
Evangelia Makri, Konstantinos Xanthopoulos, Spyros Pettas, et al.
HORMONES (2024)
Closed Access
Racial and Ethnic Disparities in Cardiovascular Disease Risk Among Patients with Chronic Kidney Disease
Demilade Adedinsewo, Ivan E. Porter, Richard O. White, et al.
Current Cardiovascular Risk Reports (2022) Vol. 16, Iss. 11, pp. 145-157
Closed Access | Times Cited: 2
Demilade Adedinsewo, Ivan E. Porter, Richard O. White, et al.
Current Cardiovascular Risk Reports (2022) Vol. 16, Iss. 11, pp. 145-157
Closed Access | Times Cited: 2
Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India
SUBHASH KUMAR WANGNOO, M Shunmugavelu, Sagili Vijaya Bhaskar Reddy, et al.
Endocrine and Metabolic Science (2021) Vol. 4, pp. 100102-100102
Open Access | Times Cited: 2
SUBHASH KUMAR WANGNOO, M Shunmugavelu, Sagili Vijaya Bhaskar Reddy, et al.
Endocrine and Metabolic Science (2021) Vol. 4, pp. 100102-100102
Open Access | Times Cited: 2
Adjunctive Therapy, Including Pharmacotherapy
Dalal Y. Al-Bazz, John Wilding
(2022), pp. 279-296
Closed Access | Times Cited: 1
Dalal Y. Al-Bazz, John Wilding
(2022), pp. 279-296
Closed Access | Times Cited: 1
Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors
Naoya Shimizu, Akifumi Ogawa, Akinori Hayashi, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 7, pp. 108225-108225
Closed Access | Times Cited: 1
Naoya Shimizu, Akifumi Ogawa, Akinori Hayashi, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 7, pp. 108225-108225
Closed Access | Times Cited: 1
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?
Shailaja Kale, Abd A. Tahrani
Metabolism Open (2021) Vol. 10, pp. 100082-100082
Open Access | Times Cited: 1
Shailaja Kale, Abd A. Tahrani
Metabolism Open (2021) Vol. 10, pp. 100082-100082
Open Access | Times Cited: 1
A empagliflozina inibe a atividade do NHE3 no túbulo proximal, preserva a taxa de filtração glomerular e restaura a euvolemia em ratos não diabéticos com insuficiência cardíaca
Flávio Araújo Borges
(2023)
Open Access
Flávio Araújo Borges
(2023)
Open Access
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review
Kiran Prasad Moparthi, Majdah T Al Rushaidi, Meghana Reddy Muddam, et al.
Cureus (2023)
Open Access
Kiran Prasad Moparthi, Majdah T Al Rushaidi, Meghana Reddy Muddam, et al.
Cureus (2023)
Open Access
Beyond Glycemic Control: Mechanistic Insights Into SGLT-2 Inhibitors in Heart Failure Management
Shreya Garg, Sai Gautham Kanagala, FNU Anamika, et al.
Cardiology in Review (2023)
Closed Access
Shreya Garg, Sai Gautham Kanagala, FNU Anamika, et al.
Cardiology in Review (2023)
Closed Access
Stopping Empagliflozin Unmasks Heart Failure
Morolake Amole
Federal practitioner (2021), Iss. 38 (Suppl 4)
Open Access
Morolake Amole
Federal practitioner (2021), Iss. 38 (Suppl 4)
Open Access
